General Hospital Psychiatry
Volume 30, Issue 1 , Pages 40-48 , January 2008

Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis

  • Dawn M. Ehde, Ph.D.

      Affiliations

    • Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    • Corresponding Author InformationCorresponding author. Department of Rehabilitation Medicine, Seattle, WA 98104-2499, USA. Tel.: +1 206 731 2811; fax: +1 206 731 8580.
    • ,
  • George H. Kraft, M.D.

      Affiliations

    • Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    • Department of Neurology, University of Washington School of Medicine, Seattle, WA 98195, USA
    • ,
  • Lydia Chwastiak, M.D., M.P.H.

      Affiliations

    • Department of Psychiatry, Yale School of Medicine, New Haven, CT 06519, USA
    • ,
  • Mark D. Sullivan, M.D., Ph.D.

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA
    • ,
  • Laura E. Gibbons, Ph.D.

      Affiliations

    • Department of Psychosocial and Community Health, University of Washington School of Nursing, Seattle, WA 98195, USA
    • ,
  • Charles H. Bombardier, Ph.D.

      Affiliations

    • Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    • ,
  • Rohini Wadhwani, B.A.

      Affiliations

    • Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA

Received 19 June 2007 ,Accepted 8 August 2007.

References 

  1. Patten SB, Beck CA, Illiams WJV, et al. Major depression in multiple sclerosis: a population based perspective. Neurology. 2003;61:1524–1527
  2. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler. 2000;6:115–120
  3. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry. 1987;9:426–434
  4. Ehde DM, Bombardier CH. Depression in persons with multiple sclerosis. Phys Med Rehabil Clin N Am. 2005;16:437–448
  5. Clark CM, Fleming JA, Li D, Oger J, Klonoff H, Paty D. Sleep disturbance, depression, and lesion site in patients with multiple sclerosis. Arch Neurol. 1992;49:641–643
  6. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002;16:381–397
  7. Arnett PA, Higginson CI, Voss WD, Bender WI, Wurst JM, Tippin JM. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology. 1999;13:546–556
  8. Mohr DC, Goodkin DE, Likosky W, Gatto N, Bauman KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–533
  9. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002;205:51–58
  10. Wang JL, Reimer MA, Metz LM, Patten SB. Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med. 2000;30:309–317
  11. Williams RM, Turner AP, Hatzakis M, Bowen JD, Rodriquez AA, Haselkorm JK. Prevalence and correlates of depression among veterans with multiple sclerosis. Neurology. 2005;64:75–80
  12. Cetin K, Johnson KL, Ehde DM. Kuehn CM, Amtmann D, Kraft G. Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample. Mult Scler 2007;13:1046–53.
  13. Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis: review and meta-analysis. Clinical Psychology: Science and Practice. 1999;6:1–9
  14. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493–1497
  15. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive–behavior therapy, supportive–expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69:942–949
  16. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;12:56–62
  17. American Psychiatric Association . Practice guidelines for the treatment of patients with major depressive disorder. Am J Psychiatry Supplement. 2000;157(4):1–78
  18. Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159:1862–1868
  19. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401
  20. Haringsma R, Engels GI, Beekman AT, Spinhoven P. The criterion validity of the Center for Epidemiological Studies Depression Scale (CES-D) in a sample of self-referred elders with depressive symptomatology. Int J Geriatr Psychiatry. 2004;19:558–563
  21. Myers JK, Weissman MM. Use of a self-report symptom scale to detect depression in a community sample. Am J Psychiatry. 1980;137:1081–1084
  22. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiology. 1977;106:203–214
  23. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington (DC): American Psychiatric Press, Inc.; 1996;
  24. Bowen J, Gibbons L, Gianas A, Kraft G. Self-administered Expanded Disability Status Scale with function system scores correlates well with physician-administered test. Mult Scler. 2001;7:201–206
  25. Miranda J, Chung JY, Green BL, et al. Treating depression in predominantly low-income young minority women: a randomized controlled trial. JAMA. 2003;290:57–165
  26. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J. Outcome definitions and predictors in depression. Psychother Psychosom. 1998;67:266–270
  27. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed.. Washington (DC): American Psychiatric Association; 1994;
  28. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry. 1974;7:79–110
  29. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty DW. Recent developments in the assessment of quality of life in multiple sclerosis. Mult Scler. 1999;5(4):251–259
  30. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): 1. Conceptual framework and item selection. Med Care. 1992;30:473
  31. Multiple Sclerosis Council for Clinical Practice Guidelines . Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Multiple Sclerosis Council for Clinical Practice Guidelines; 1998;
  32. Sullivan JJL, Edgley K, Dehoux E. A survey of multiple sclerosis: Part 1. Perceived cognitive problems and compensatory strategy use. Can J Rehabil. 1990;4:99–105
  33. Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction with Life Scale. J Pers Assess. 1985;49:71–75
  34. Hamilton M. Treatment of anxiety states: III. Components of anxiety and their response to benactyzine. J Ment Sci. 1958;104:1062–1068
  35. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840–1847
  36. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics?. Int J Neuropsychopharmacol. 2002;5:193–197
  37. Hirschfeld RM, Keller MB, Panico S, et al. The national Depressive and Manic–Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333–340
  38. Katon WJ, Unutzer J, Simon G. Treatment of depression in primary care: where we are, where we can go. Med Care. 2004;42:1153–1157
  39. Lin EH, Katon WJ, Simon GE, et al. Low-intensity treatment of depression in primary care: is it problematic?. Gen Hosp Psychiatry. 2000;22:78–83
  40. Mohr DC, Hart S, Fonareva I, Tasch ET. Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler. 2006;12:204–208
  41. Gensichen J, Beyer M, Muth C, Gerlach FM, Von Korff M, Ormel J. Case management to improve major depression in primary health care: a systematic review. Psychol Med. 2005;35:1–8
  42. Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006;166:2314–2321
  43. Neumeyer-Gromen A, Lampert T, Stark K, Kallischnigg G. Disease management program for depression: a systematic review and meta-analysis of randomized controlled trials. Med Care. 2004;42:1211–1221
  44. Simon GE, Katon WJ, Lin EHB, Rutter C, Manning WG, VonKorff M, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry. 2007;64:65–72

☆ Disclosure: GlaxoSmithKline provided the study medications (placebo and active) but did not participate in study conceptualization, study design, data analyses or manuscript preparation.

PII: S0163-8343(07)00142-9

doi: 10.1016/j.genhosppsych.2007.08.002

General Hospital Psychiatry
Volume 30, Issue 1 , Pages 40-48 , January 2008

Article Tools

* Image Usage & Resolution